Estimating the Prognosis of Hepatitis C Patients Infected by Transfusion in Canada between 1986 and 1990

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Medical decision making

• Publication date

  2004-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/0272989X03261568PMID 15005951
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-term follow-up of chronic post-transfusion non-A, non-B hepatitis: clinical and histological outcome.

  2008cited by this paper
• Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers.

  2008cited by this paper
• Histological evolution of chronic hepatitis C. Factors related to progression.

  2008cited by this paper
• Indications for interferon/ribavirin therapy in hepatitis C patients: findings from a survey of Canadian hepatologists.

  2003cited by this paper
• Plan to put outside managers in NHS is criticised

  2002cited by this paper
• Hepataitis C compensation case could open floodgate to claims

  2002cited by this paper
• NHS told to pay 10m (pounds sterling) to patients infected with hepatitis C.

  2001cited by this paper
• Plan to end age discrimination in NHS is launched

  2001cited by this paper
• Australia eyeing Canada's rural MDs

  2000cited by this paper
• Blood money.

  1999cited by this paper
• Interferon treatment for chronic hepatitis B or C infection: costs and effectiveness.

  1998cited by this paper
• Hepatitis C

  1998cited by this paper
• ESTIMATING THE NUMBER OF BLOOD TRANSFUSION RECIPIENTS INFECTED BY HEPATITIS C VIRUS IN CANADA, 1960-85 AND 1990-92

  1998cited by this paper
• Hepatitis C.

  1998cited by this paper
• Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

  1998cited by this paper
• Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

  1998cited by this paper
• Clinical outcome of hepatitis C as a function of mode of transmission

  1998cited by this paper
• Predictors of patient and graft survival following liver transplantation for hepatitis C

  1998cited by this paper
• Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

  1998cited by this paper
• Determinants of outcome of compensated hepatitis C virus‐related cirrhosis

  1998cited by this paper
• The hepatitis C disaster.

  1998cited by this paper
• Compensation for Canada's hepatitis C victims to be re-evaluated.

  1998cited by this paper
• Prognosis of chronic hepatitis c: Results of a large, prospective cohort study

  1998cited by this paper
• Hepatitis C as medical misadventure.

  1998cited by this paper
• Primer on Medical Decision Analysis: Part 5—Working with Markov Processes

  1997cited by this paper
• Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.

  1997cited by this paper
• Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C.

  1997cited by this paper
• Estimates of the Cost-Effectiveness of a Single Course of Interferon-2b in Patients with Histologically Mild Chronic Hepatitis C

  1997cited by this paper
• Cost-Effectiveness of 6 and 12 Months of Interferon- Therapy for Chronic Hepatitis C

  1997cited by this paper
• Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients.

  1997cited by this paper
• Natural history of hepatitis C

  1997cited by this paper
• A survey of red cell use in 45 hospitals in central Ontario, Canada

  1996cited by this paper
• The natural course of chronic hepatitis C: A comparison between patients with genotypes 1 and 2 hepatitis C viruses

  1996cited by this paper
• The long‐term pathological evolution of chronic hepatitis C

  1996cited by this paper
• Identification of numerous hepatitis C virus genotypes in Montreal, Canada

  1996cited by this paper
• Long-term outcome of hepatitis C infection after liver transplantation.

  1996cited by this paper
• Subtyping of hepatitis C virus isolates by a line probe assay using hybridization

  1995cited by this paper
• Persistent hepatitis C viremia after acute self‐limiting posttransfusion hepatitis C

  1995cited by this paper
• Presentation of hepatitis C in a unique uniform cohort 17 years from inoculation

  1995cited by this paper
• Treatment of chronic type B and C hepatitis with interferon alfa: An economic appraisal

  1995cited by this paper
• Clinical outcomes after transfusion-associated hepatitis C.

  1995cited by this paper
• The natural course of chronic hepatitis C.

  1994cited by this paper
• Long‐term survival after blood transfusion

  1994cited by this paper
• Methods for pooled analyses of epidemiologic studies.

  1994cited by this paper
• Genotyping of Canadian hepatitis C virus isolates by PCR

  1994cited by this paper
• The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C

  1994cited by this paper
• Epidemiology and long term prognosis of hepatitis C virus infection in Japan.

  1993cited by this paper
• A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis

  1993cited by this paper
• Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis.

  1993cited by this paper
• Natural course of chronic hepatitis C.

  1993cited by this paper
• Histological patterns of prolonged hepatitis C infection.

  1993cited by this paper
• Methods for Pooled Analyses of Epidemiologic Studies

  1993cited by this paper
• Non-A, Non-B Post-Transfusion Hepatitis: Looking Back in the Second Decade

  1993cited by this paper
• Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group.

  1992cited by this paper
• Long-Term Mortality after Transfusion-Associated Non-A, Non-B Hepatitis

  1992cited by this paper
• Persistence of viremia in patients with type-C chronic hepatitis during long-term follow-up.

  1992cited by this paper
• Hepatitis C in chronic liver disease: an epidemiological study based on 566 consecutive patients undergoing liver biopsy during a 10‐year period

  1992cited by this paper
• Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland.

  1991cited by this paper
• Long‐term clinical and histopathological follow‐up of chronic posttransfusion hepatitis

  1991cited by this paper
• Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV).

  1990cited by this paper
• Preliminary report on 10 patients treated with radiotherapy after radical prostatectomy for isolated elevation of serum PSA levels.

  1990cited by this paper
• Interrelationship of blood transfusion, non‐A, non‐B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus

  1990cited by this paper
• A comparison of statistical methods for combining event rates from clinical trials.

  1989cited by this paper
• The natural history of transfusion-associated infection with human immunodeficiency virus. Factors influencing the rate of progression to disease.

  1989cited by this paper
• Meta-analysis in clinical research.

  1987cited by this paper
• Risk of AIDS for recipients of blood components from donors who subsequently developed AIDS.

  1987cited by this paper
• Risk of AIDS for recipients of blood components from donors who subsequently developed AIDS

  1987cited by this paper
• Meta-analysis in clinical trials.

  1986cited by this paper
• Probabilistic Analysis of Decision Trees Using Monte Carlo Simulation

  1986cited by this paper
• Probabilistic Analysis of Decision Trees Using Symbolic Algebra

  1986cited by this paper
• Probabilistic Sensitivity Analysis Using Monte Carlo Simulation

  1985cited by this paper
• Primary hepatocellular carcinoma following non-A, non-B posttransfusion hepatitis

  1983cited by this paper
• Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: evidence of progression to liver cirrhosis.

  1982cited by this paper
• Non-A, non-B post-transfusion hepatitis.

  1977cited by this paper
• The natural history of hepatitis.

  1969cited by this paper

• Another Step Toward Hepatitis C Elimination: An Economic Evaluation of an Irish National Birth Cohort Testing Program.

  2022cites this paper
• Cost-Utility Analysis of Vasoconstrictors Plus Albumin in the Treatment of Thai Patients with Type 1 Hepatorenal Syndrome

  2021cites this paper
• Cost‐effectiveness analysis of hepatitis C virus (HCV) point‐of‐care assay for HCV screening

  2021cites this paper
• CEOR_A_317390 703..715

  2021cites this paper
• The health impact of delaying direct‐acting antiviral treatment for chronic hepatitis C: A decision‐analytic approach

  2020cites this paper
• Treatment of Chronic Hepatitis C in Young Children Reduces Adverse Outcomes and Is Cost-Effective Compared to Deferring Treatment to Adulthood.

  2020cites this paper
• Social values for health technology assessment in Canada: a scoping review of hepatitis C screening, diagnosis and treatment

  2020cites this paper
• Can we afford not to screen and treat hepatitis C virus infection in Canada?

  2018cites this paper
• Model-based projection of health and economic effects of screening for hepatitis C in Canada.

  2017cites this paper
• Scheduling Optimization of Home Health Care Service Considering Patients’ Priorities and Time Windows

  2017cites this paper
• Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis.

  2017cites this paper
• Future complications of chronic hepatitis C in a low-risk area: projections from the hepatitis c study in Northern Norway

  2017cites this paper
• A Parallel Sliding Region Algorithm to Make Agent-Based Modeling Possible for a Large-Scale Simulation: Modeling Hepatitis C Epidemics in Canada

  2016cites this paper
• КЛИНИЧЕСКИЕ ПРЕИМУЩЕСТВА И ЭКОНОМИЧЕСКАЯ ЭФФЕКТИВНОСТЬ ПРОТИВОВИРУСНОЙ ТЕРАПИИ У БОЛЬНЫХ ХРОНИЧЕСКИМ ГЕПАТИТОМ С В УСЛОВИЯХ БЮДЖЕТНОГО ЗДРАВООХРАНЕНИЯ

  2016cites this paper
• Visualizing the hepatic vascular architecture using superb microvascular imaging in patients with hepatitis C virus: A novel technique.

  2016cites this paper
• Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6

  2016cites this paper
• Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons

  2016cites this paper
• Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada

  2016influential citation
• Disease burden of chronic hepatitis C among immigrants in Canada

  2015cites this paper
• Cost-effectiveness of screening for hepatitis C in Canada

  2015cites this paper
• Direct-Acting Antiviral Agents for Chronic Hepatitis C Genotype 1

  2014influential citation
• A Bayesian framework for describing and predicting the stochastic demand of home care patients

  2014cites this paper
• Risk factors for liver-related mortality in chronic hepatitis C patients: A deceased case-living control study

  2014cites this paper
• Risk factors for liver-related mortality in chronic hepatitis C patients: a deceased case-living control study.

  2014cites this paper
• Hepatitis C virus-associated glomerulonephritis.

  2013cites this paper
• Chronic Hepatitis C among Immigrants Living in Canada: Natural History, Disease Burden, and Cost-effectiveness of Screening

  2013cites this paper
• Supporting Public Health Policy Decision-making through Economic Evaluation: Applications and Methods

  2012cites this paper
• Efficacy and cost-effectiveness of consensus interferon monotherapy with high-dose induction for hepatitis C patients with genotype 2

  2011cites this paper
• Natural history of chronic hepatitis C: genotype 1 versus genotype 6.

  2010cites this paper
• A patient stochastic model to support human resource planning in home care

  2010influential citation
• Hepatitis C and hepatocellular carcinoma: New developments in natural history and treatment

  2009cites this paper
• Undiagnosed hepatitis C on the general medicine and trauma services of two urban hospitals.

  2009cites this paper
• Low uptake of treatment for hepatitis C virus infection in a large community‐based study of inner city residents

  2009cites this paper
• Prognosis of hepatitis C virus‐infected Canadian post‐transfusion compensation claimant cohort

  2009cites this paper
• Health care costs of persons with newly diagnosed hepatitis C virus: a population‐based, observational study

  2008cites this paper
• Barriers associated with the treatment of hepatitis C virus infection among illicit drug users.

  2008cites this paper
• Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors.

  2008cites this paper
• Liver histology in patients on hemodialysis with chronic hepatitis C viral infection.

  2008cites this paper
• Immunopathogenesis in hepatitis C virus cirrhosis.

  2007cites this paper
• The hepatitis C sequence database in Los Alamos

  2007cites this paper
• Management of solitary 1 cm to 2 cm liver nodules in patients with compensated cirrhosis: a decision analysis.

  2007cites this paper
• Supporting Informed Decisions Pegylated Interferon Combined with Ribavirin for Chronic Hepatitis C Virus Infection: An Economic Evaluation

  2007cites this paper
• Cost‐effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy

  2006cites this paper
• Hepatitis C databases, principles and utility to researchers

  2006cites this paper
• Hepatitis C, illicit drug use and public health: does Canada really have a viable plan?

  2006cites this paper
• Hepatitis C, Illicit Drug Use and Public Health

  2006cites this paper
• Predictors of antiviral therapy in a post-transfusion cohort of hepatitis C patients.

  2006cites this paper
• [Natural history of hepatitis B infection].

  2006cites this paper
• Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada.

  2005cites this paper
• Los Alamos Hepatitis C Immunology Database

  2005cites this paper
• Treatment of hepatitis C

  2005cites this paper
• The Los Alamos hepatitis C sequence database

  2005cites this paper
• Examination of the value of treatment of decompensated viral hepatitis patients by intentionally coinfecting them with an apathogenic IBDV and using the lessons learnt to seriously consider treating patients infected with HIV using the apathogenic hepatitis G virus.

  2004cites this paper
• Improving the accuracy of long‐term prognostic estimates in hepatitis C virus infection

  2004cites this paper
• INDEX to MEDICAL DECISION MAKING

  2004cites this paper
• Prevention of hepatitis C virus-related hepatocellular carcinoma.

  2004cites this paper